Načítá se...
Repositioning Trimebutine Maleate as a Cancer Treatment Targeting Ovarian Cancer Stem Cells
The overall five-year survival rate for late-stage patients of ovarian cancer is below 29% due to disease recurrence and drug resistance. Cancer stem cells (CSCs) are known as a major contributor to drug resistance and recurrence. Accordingly, therapies targeting ovarian CSCs are needed to overcome...
Uloženo v:
| Vydáno v: | Cells |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8072797/ https://ncbi.nlm.nih.gov/pubmed/33923707 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells10040918 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|